Circassia is conducting the study in the field of cat-dander allergy, and aims to complete the trial in the coming months. This clinical study builds on the results of a previous double-blind, placebo-controlled Phase II trial, which provided proof-of-concept for the ToleroMune technology.
The current trial will study both safety and surrogate efficacy outcomes, following escalating doses administered via two different routes (intradermal and subcutaneous). The study is taking place in Germany in up to 11 patient cohorts, with each containing eight subjects with cat-dander allergy. Trial recruitment is progressing rapidly, and dosing is complete in the first patient cohort and ongoing in the second and third groups of patients.